Recent Advances in the Delivery of Chemotherapeutic Agents

Jeswani, Gunjan; Paul, Swarnali Das

doi:10.1016/b978-0-323-52727-9.00015-7

Cited by 10 publications

(10 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(). In addition, zorubicin (NSC164011), a benzoylhydrazine analog of daunorubicin, which shares similar effects with daunorubicin in inhibition of carcinogenesis, is now in a phase III clinical trial for treatment of breast cancer (Jeswani and Paul, ). Meanwhile, the reason why daunorubicin (NSC82151) and zorubicin (NSC164011) could be regarded as candidate drugs can also be found in our drug functional similarity network.…”

Section: Resultsmentioning

confidence: 99%

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Zheng

Kong

et al. 2019

Molecular Oncology

View full text Add to dashboard Cite

Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of candidate drugs (PriorCD), for the prioritization of candidate cancer drugs based on a global network propagation algorithm and a drug–drug functional similarity network constructed by integrating pathway activity profiles and drug activity profiles. This provides a new approach to drug repurposing by first considering the drug functional similarities at the pathway level. The performance of PriorCD in drug repurposing was evaluated by using drug datasets of breast cancer and ovarian cancer. Cross‐validation tests on the drugs approved for the treatment of these cancers indicated that our approach can achieve area under receiver‐operating characteristic curve (AUROC) values greater than 0.82. Furthermore, literature searches validated our results, and comparison with other classical gene‐based repurposing methods indicated that our pathway‐level PriorCD is comparatively more effective at prioritizing candidate drugs with similar therapeutic effects. We hope that our study will be of benefit to the field of drug discovery. In order to expand the usage of PriorCD, a freely available R‐based package, PriorCD, has been developed to prioritize candidate anticancer drugs for drug repurposing.

show abstract

Section: Resultsmentioning

confidence: 99%

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Zheng

Kong

et al. 2019

Molecular Oncology

View full text Add to dashboard Cite

show abstract

“…Antitumor antibiotics are amongst the most important ANP agents administered for chemotherapeutic purposes. They mainly to bind to DNA or RNA through intercalation and stop cancer cells from growing [115]. DOX and epirubicin [116] are the only two antitumor antibiotics that have been investigated until now [93].…”

Section: Removal Of Antitumor Antibiotics In Stpmentioning

confidence: 99%

Environmental Remediation of Antineoplastic Drugs: Present Status, Challenges, and Future Directions

et al. 2020

View full text Add to dashboard Cite

The global burden of cancer is on the rise, and as a result, the number of therapeutics administered for chemotherapy is increasing. The occupational exposure, recalcitrant nature and ecotoxicological toxicity of these therapeutics, referred to as antineoplastic (ANP) drugs, have raised concerns about their safe remediation. This review provides an overview of the environmental source of ANPs agents, with emphasis on the currently used remediation approaches. Outpatient excreta, hospital effluents, and waste from pharmaceutical industries are the primary source of ANP waste. The current review describes various biotic and abiotic methods used in the remediation of ANP drugs in the environment. Abiotic methods often generate transformation products (TPs) of unknown toxicity. In this light, obtaining data on the environmental toxicity of ANPs and its TPs is crucial to determine their toxic effect on the ecosystem. We also discuss the biodegradation of ANP drugs using monoculture of fungal and bacterial species, and microbial consortia in sewage treatment plants. The current review effort further explores a safe and sustainable approach for ANP waste treatment to replace existing chemical and oxidation intensive treatment approaches. To conclude, we assess the possibility of integrating biotic and abiotic methods of ANP drug degradation.

show abstract

“…Consequently, it should not come as a shock that research into the cancer-preventing qualities of antioxidants has been prevalent, specifically in protecting against gastrointestinal cancers. Over the past few decades, gastrointestinal cancer has been the focus of more study and molecular discoveries than all other solid tumor types combined [ 8 , 9 ]. Cigarette smoking, heavy alcohol use, advanced age, certain viruses and bacteria, chronic pancreatitis, obesity, and being overweight are all conditions that raise the chances of gastrointestinal cancer.…”

Section: Introductionmentioning

confidence: 99%

“…They impede the action of essential enzymes, preventing the transmission of signals required for developing cancer cells. In this way, blocking these cell signals can stop the progression of cancer and its ability to metastasize [ 9 , 16 ]. Small compounds can be used as medicines to silence proteins in cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Natural Small Molecules in Gastrointestinal Tract and Associated Cancers: Molecular Insights and Targeted Therapies

et al. 2022

View full text Add to dashboard Cite

Gastric cancer is one of the most common cancers of the gastrointestinal tract. Although surgery is the primary treatment, serious maladies that dissipate to other parts of the body may require chemotherapy. As there is no effective procedure to treat stomach cancer, natural small molecules are a current focus of research interest for the development of better therapeutics. Chemotherapy is usually used as a last resort for people with advanced stomach cancer. Anti-colon cancer chemotherapy has become increasingly effective due to drug resistance and sensitivity across a wide spectrum of drugs. Naturally-occurring substances have been widely acknowledged as an important project for discovering innovative medications, and many therapeutic pharmaceuticals are made from natural small molecules. Although the beneficial effects of natural products are as yet unknown, emerging data suggest that several natural small molecules could suppress the progression of stomach cancer. Therefore, the underlying mechanism of natural small molecules for pathways that are directly involved in the pathogenesis of cancerous diseases is reviewed in this article. Chemotherapy and molecularly-targeted drugs can provide hope to colon cancer patients. New discoveries could help in the fight against cancer, and future stomach cancer therapies will probably include molecularly formulated drugs.

show abstract

Recent Advances in the Delivery of Chemotherapeutic Agents

Cited by 10 publications

References 52 publications

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities

Environmental Remediation of Antineoplastic Drugs: Present Status, Challenges, and Future Directions

Natural Small Molecules in Gastrointestinal Tract and Associated Cancers: Molecular Insights and Targeted Therapies

Contact Info

Product

Resources

About